Coldstream Capital Management Inc. Increases Stake in Eli Lilly and Company $LLY

Coldstream Capital Management Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 25.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 42,418 shares of the company’s stock after acquiring an additional 8,659 shares during the period. Coldstream Capital Management Inc.’s holdings in Eli Lilly and Company were worth $32,365,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Aspire Private Capital LLC raised its holdings in Eli Lilly and Company by 14.7% during the third quarter. Aspire Private Capital LLC now owns 2,715 shares of the company’s stock worth $2,072,000 after purchasing an additional 348 shares in the last quarter. Aldebaran Financial Inc. boosted its holdings in Eli Lilly and Company by 22.1% in the 3rd quarter. Aldebaran Financial Inc. now owns 1,762 shares of the company’s stock valued at $1,344,000 after purchasing an additional 319 shares in the last quarter. Danske Bank A S purchased a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $512,022,000. Mizuho Markets Cayman LP increased its position in Eli Lilly and Company by 2,166.4% during the 3rd quarter. Mizuho Markets Cayman LP now owns 88,300 shares of the company’s stock worth $67,373,000 after purchasing an additional 84,404 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $1,489,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on LLY. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target for the company. Barclays started coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. Wolfe Research raised their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the stock from $1,070.00 to $850.00 in a research report on Tuesday. Finally, Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase‑3 results for EBGLYSS (lebrikizumab) expand Lilly’s immunology franchise and reduce execution risk on non‑GLP pipeline growth—a clear constructive catalyst for longer‑term revenue diversification. Lilly EBGLYSS Phase 3 Pediatric Results
• Positive Sentiment: Several Wall Street firms remain bullish—some raising targets and highlighting Zepbound/Mounjaro momentum and distribution initiatives (e.g., Employer Connect)—which supports medium‑term sales and margin expectations. Wall Street Firms Turn Bullish on Eli Lilly
• Neutral Sentiment: Disclosure that a member of Congress purchased LLY shares is a data point that can increase watchlist activity but is not a fresh fundamental catalyst. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: HSBC downgraded LLY to “reduce” (cutting its price target to $850) citing pricing pressure, rising competition, and what it sees as overstated obesity‑market growth—this downgrade triggered selling and repricing of growth expectations. Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
• Negative Sentiment: Competitive threats intensified after reports of a new GLP‑1 oral pill showing strong weight‑loss data and commentary about Novo Nordisk rivalry; investors are re‑assessing Lilly’s pricing power and market share durability. Structure Weight‑Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Market writeups highlight valuation risk: with high multiples already priced for continued GLP‑1 growth, any downgrade or slower uptake triggers outsized downside as investors rotate away from stretched growth names. Why Eli Lilly Stock Just Dropped

Eli Lilly and Company Stock Down 5.9%

Shares of NYSE:LLY opened at $931.03 on Wednesday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $879.65 billion, a P/E ratio of 40.57, a P/E/G ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The stock’s fifty day simple moving average is $1,033.54 and its 200-day simple moving average is $955.52.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.